Whatareyouropinions on useofamoxicillin-clavulanate at a daily dose of20 mglkg and cefaclorgiven twice daily to treat acuteotitismedia(AOM)?
gradationin histologic response to treatment dose; thus, antibiotic concentrationin the middle ear is important in the cure. We do not know how these experimental studies relate to the doses mentioned,becausewe haven't studied human middle ear effusion concentrations.
Dr RobertWilliams et al 2 recently publisheda meta-analysis ofantibiotics usedinpreventing recurrent AOMandin treating otitismediawitheffusion (OME). Pleasecommenton the implications ofthe resultsandconclusions ofthat studyfor clinical practice. Doyouexpectthisstudyor otherstobe thebasisforthe Agencyfor Health Care PolicyResearch Guidelines for DME Management?
Drs Giebink and Canafax: Dr Richard Rosenfeld et al have a similarstudy in press in TheJournalofPediatrics'; their conclusionswere different than those expressed by Williamset a1. 2 The difference arose primarily from the use of different inclusion criteria. Meta-analysis results are highly dependent on these criteria, and we suggest that both studies be read before current clinical treatment is altered. The OME treatment panel is a collaborative effort of the American Academy of Otolaryngology, the American Academy of Pediatrics, and the American Academy of Family Practice. A draft report was recently published for comment. A final report is not expected for several months.
Has anyone tried treating serous otitis media with nitrous oxidein an attemptto avoidtympanostomy tubesby increasing nitrogen in the middleear?
Dr Bernstein:I don't know ifnitrous oxide would have a longterm effect. Nitrous oxide would increase the pressure in the middle ear immediately, but nitrous oxide is even more soluble thancarbon dioxide, which means it would be absorbed into the tissue withinseconds. So, it's not a bad idea ifyou have a badly atelectatic ear and you want to put a tube in, because it will immediately diffuse into the middle ear space and will increase the volume of the middle ear, perhaps allowing you to put a tube in. But it couldn't possibly be used as long-term therapy because it's a very rapidly diffusing gas.
Dr Paparella:I don'tknow ifit relates, but occasionallywe see childrenor adults who definitely have OME in the clinic; we take them to the operating room, and it "disappears," This may be the result of tubal insufflation, the use of nitrous oxide, or disease remission.
Dr Bernstein: I don't think it's tubal insufflation. I think it is this conceptof gas movement from the blood into the middle ear via the middle ear mucosal blood vessels.
Howmanyweeksor monthsdoesit takefor permanent middle 31 ear changes of chronic otitis media to develop, and is there anything that can be done to preventprogression?
Dr Meyerhoff: We again have to go to the animal model, in which irreversible tissue pathology can occur 10 to 12 days following bacterial inoculation.We don't have the advantagein humansofbeing able to have a window intotheir ear, so we don't really know the chronology in humans. I think that one of the important things to remember in otitis media is that any time in the continuum, up to irreversible tissue pathology, the process can resolve and return to a normal ear. Treatment is going to influence this,andthe earliertreatmentis given,thebetterchance you have of avoiding irreversible tissue pathology.
Wehaveseenthetypesofbacteriawhichpredominate inAOM.
In chronic OME,50% ofchildren studiedby Dr Itzhak Brook culturedanaerobes. What is your definition ofchronic OMEin those children, and do you believe that anaerobic bacteria contribute to the pathogenesis ofADM?
Dr Chole: The article thatI mentioned by Brook and Burke 4 selected patients whohadchronic OME, and there was a surprisingly high incidence of anaerobes.
Dr GiebiDk: A number of studies have failed to culture anaerobes in both AOM and chronic OME in all but a few cases.From a clinical perspective, it is unlikely that anaerobic bacteria contribute to chronic OME. For example, in chronic suppurative otitis media, antibiotics active against Pseudomonas aeruginosa and Staphylococcus aureusare effective, and these drugs don't have an anaerobic spectrum.
Dr Bernstein: In our studies, when the tympanic membrane was cultured prior to myringotomy, we have cultured anaerobic bacteria such as Propionibacterium acnesfromthe earcanal.But we've almost never found this organism in the middle ear. I also want to em-phasize thatwe may beinappropriately focusing on the middle ear bacteria. Bacteria that cause otitis media are organisms nonnally present in healthy children. Nontypeable Hemophilus injluent.ae, Moraxellacatarrhalis, andperhapsStreptococcus pneumoniae are present in the nasopharynx in small quantities all the time. They are not usually invasive organisms. Something happens to make them invasive, probably a viral infection.The mucociliarysystem does not function nonnally as a resultof thisviraIinfection.These bacterialorganismsreplicate in the mucusandsomehowget intothe middleearandthesinuses. We must also consider the host response. Inflammatory cellsare recruited, and colony-stimulatingfactors activate the cells, prolong their survival,andcause the release of inflammatorymediators. Rather than looking for a new antibiotic, we should focus on the inflammatory aspect of otitis media. We have to look at other modalities of treatment and try to down-regulate some of these inflammatory mediators that cause a lot of damage to middle ear tissue.
Any comments on topicalciprofloxacin for cholesteatoma?
Dr Chole: A recent nonblinded but randomized study compared topical ciprofloxacin powder to intravenous gentamicin for susceptible Pseudomonas chronic otitis media with drainage.SCiprofloxacin was more effective than intravenous gentamicin. A surprisingresult. I don't know exactlyhow to applythat kindof clinicalinformation,sincetheuse of topicalciprofloxacin powderis not an approved use of that drug. As far as I am aware, there is no ototoxicity of ciprofloxacin in the middle ear. So I think it has great promise to be a muchmore effectiveand maybe safermethodof~ting the opendrainingear. Furtherstudiesare required before it can be adopted clinically; in the study that I reviewed, there were no adverse effects of topical drug.
Dr Meyerhoff:There was also a recentstudyin NorthCarolina on toxicityof topicalciprofloxacin, and we have studiedit in our laboratory. It seems not to be toxic to the inner ear.
What abouttoxicity ofquinolone antibiotics to themiddleear ossiclesi The majortoxicity of'quinolones isoncartilage, atleast in weight-bearing joints.
Dr Chole: The use of ciprofloxacin and other quinolones is restrictedto adults because of its possible effects on growth; it is toxicto chondrocytes,A lot of the toxicityhas beendemonstrated in culture. It is thought that it may affect growth if given systemicallyoverlongperiods.Whethertopicaluseofquinolones will have similar effects is unknown. I would estimate that they probably would have minimal effects, since absorption to the mucosal surface is probably negligible, and getting anywhere near the growth center of an ossicle would bea remote chance. I would be concerned with the ototoxicity, but as Dr Meyerhoff said, preliminary results have not shown ototoxicity.
Arebonegrowth centersclosertothesurface intheeustachian tube? Sincethetopicaldrugwouldprobably bewasheddownthe -tube,
Dr Chole: No. The cartilage of the eustachian tube might be affected in a growingchild -a theoretical concern.
What aretheindications/or removing a pressure equalization tube that has not extruded on its own; and what causesposttympanostomy otorrhea? Howshouldit be managed, andcan it be prevented?
Dr Levine: Before I looked at the subject of tube removal, I thought that after a tube was in place for 2 years, it should be removed because the chances of perforation were higher. However, data on this subject are not strong. The duration of intubation is probably not a critical factor. I seemany children with otorrhea and tubes unresponsiveto topical and oral antibiotics. Some of these children have had tube removal, and the otorrhea ceases withina short time. Dr Giebink uses parenteral antipseudomonal and antistaphylococcal antibiotics in some of these persistingcases, and we've had success even leaving the tube in place.So absoluteindicationsfor removal of tubes may not exist right now, but longer-term intubation and otorrhea are relative indicationsfor tube removal. I don't have any answers as to the cause of posttympanostomyotorrhea.
Dr Giebink: Dr Pat Antonelli recently completed a series of experiments in the chinchilla otitis media model designed to understandthe cause of pseudomonalchronic suppurativeotitis media. He found that after inoculating Pseudomonas into the nose, only abnormal ears -ie, those with a tube or prior AOM -developed suppurative infection; normal ears did not.6, 7 It seems possible that chronic antibiotic use in some children selects these resistant Pseudomonas, setting up the child for suppurativeotitis after a tube is in place.
Dr Chole: We just finished a study with Xomed-Treaee, We impregnatedtympanostomytubes with silver oxide, which renders surfaces resistant to bacterial growth. We anticipated that impregnated tubeswouldinhibitcolonizationinrepeatedotorrhea, This study was done using a double-blind and randomized design.A total of 250 ears were involvedin the study at multiple centers.Silveroxide-impregnated tubesdecreasedthenumberof episodes of postoperative otorrhea by 50%. The use of silver oxide-impregnated silicone tympanostomy tubes has been presented to the Food and Drug Adminisuation for approval. We will present a complete report at theSpring Meetings.
Dr Paparella:So often we look at a foreignbody reactionas an explanation for postoperative otorrhea. I guess that's possible, but generallyspeaking,metals,silicones,and Teflon are innocuous. Undetected silent or subclinical otitis media is far more prevalent than we realize.
Howlongmusta motherbreast-feedforthepositive effectsof otitismediaprevention to be observed?
Dr Giebink: I'm familiar with two studies thatexamined the effect of breast-feeding on OME and AOM. Both showed a significant effect with any breast-feeding. There was about a 60% to 70% reduction in AOM with 3 or 4 months of breastfeeding; there wasn't much greater effect with breast-feeding duration to 12 months.
Ifa childis on eitheramoxicillin or sulfonamide prophylaxis, do we needtofollow laboratory work,and arethereany studies withotherchemoprophylactic agents?
Dr Giebink:I do not get any laboratorywork with amoxicillin prophylaxis. If I use sulfisoxazole prophylaxis, I get a white blood cell count, differential, and hemoglobin when I begin.
There is occasionally dose-dependent myelosuppression, but I do not believe it is clinically significant. Trimethoprim-sulfamethoxazolehas also been used for chemoprophylaxisof recurrent ADM. However,the Food and Drug Administrationspecifically recommends against this practice. I agree, because the adverse effects, severe exfoliative dennatitis and Stevens-Johnson syndrome, don't disappear quickly. These patients often require intensive anti-inflammatory treatment to control the severe reactions.
Whatis the role ofantihistamines in treating otitismedia?
Dr Bernstein: Evidence to date does not support the use of antihistamines. We think of middle ear effusion as a result of eustachian tube obstruction and inflammation. There are multiple inflammatory mediators; histamine is only one. The theoretical concept of using antihistamines and the clinical efficacy of using them in controlled, carefully randomized, double-blind studiesdoes not supporttheir use alone in otitis media or, for that matter, sinusitis.
It wasmentioned thattubescanbeusedto treatchronicOME lastingat least3 months.ls this3 monthsarbitrary, or isit based on scientifIC in/ormation? Dr Giebink: It's based on epidemiologic information from a numberof centers that have looked at the naturalhistoryof OME and its resolution. After 12 weeks, about 10% of ears with prior ADM have persistent effusion. Few ears clear effusion after3 or 4 months. Dr Chole: We also have to exercise common sense about putting tubes in or doing adenoidectomy. If an ear shows anatomic evidence of progression toward retraction pocket cholesteatomas,if the long process of the incus is eroding, or if there are significant anatomicchangesin the tympanicmembrane,it is unreasonable to wait a long time before doing a myringotomy with tube and/or adenoidectomy. Dr GiebiDk: Thisis animportantpointfornonotolaryngologists in the audience. A study by Schwartz et alB reported that the majorityof children with cholesteatomahad been referred to the otolaryngologist for management of chronic OME and placement of tubes. Cholesteatoma is a very silent disease.
Dr Paparella:As I recall from an International Symposiumon OtitisMediaand its Working Groups, indicationfortympanostomy tubes started at 2 monthsand later was considered to be3 months. To me the indication is the existence of chronic middle ear effusion, and we use these time points as relative guidelines.
Pleasesummarize themanagement plan/or children present. . . ing with recurrent ADM andchronicOME.
Dr Giebink: Dr Canafax discussed a reasonable approach to antibiotic selection. Almost all of the studies reported treatment for 10 days. One study looked at shorter treatment, with equal efficacy in children without otorrhea. but worse efficacy in the faceof acuteotorrhea,Studies in the Netherlands have examined no antibiotic treatment of ADM. These studies, however, are severely criticized because the severity of the disease wasn't clearly described in the publications, and the follow-up was extremely short. An international panel discussingmanagement of otitis in Oita, Japan, recently reported that almost 50% of primary care physicians in the Netherlands do treat ADM with antibiotics. As the disease becomes more recurrent, we discuss selection ofdrugs for chemoprophylaxis, use oftubes, and use of adenoidectomy.
Dr Bernstein: I also think about allergies in some of those cases, and I certainlywouldthink aboutimmunologic deficiency. I believe that a lot of children with recurrent ADM have a subtle immunologicdeficiency. Immunologic evaluation mayreveal an IgO subclass deficiency or an IgA deficiency. Although that's Dot an answer directly to the question of treatment, I think it's certainly part of the workup for patients with recurrent ADM.
Dr Oiebink: Studies done by our group and in Sweden and Finland have revealed subtle immunologic differences in otitisprone children, but I would not classify these as overt immune deficiency. However, an occasional child with recurrent ADM will have serious immune deficiency requiring immunoglobulin replacement therapy. Specific antibody responses to vaccines, especially pneumococcal polysaccharide vaccine, are often abnormal in these cases. Also, in cities with high acquired immunodeficiency syndrome prevalence, others have reported that recurrentADM is acommon presenting complaintin infants with acquired immunodeficiency syndrome.
